

# **Thaw and Culture Details**

Cell Line Name	SA02
WiCell Lot Number	SA02-FTDL-01
Provider	Cellartis
Banked By	WiCell
Thaw and Culture Recommendations	WiCell recommends thawing 1 vial into 1 well of a 6 well plate.
Culture Platform	Feeder Dependent
	Medium: hESC Medium (KOSR)
	Matrix: MEF
Protocol	WiCell Feeder Dependent Protocol
Passage Number	p27 These cells were cultured for 26 passages prior to freeze. WiCell adds +1 to the passage number to best represent the overall passage number of the cells at thaw.
Date Vialed	31-March-2009
Vial Label	SA02-FTDL-1 p27 MW 31 MAR 2009 SOPCC038A
Biosafety and Use Information	Appropriate biosafety precautions should be followed when working with these cells. The end user is responsible for ensuring that the cells are handled and stored in an appropriate manner. WiCell is not responsible for damages or injuries that may result from the use of these cells. Cells distributed by WiCell are intended for research purposes only and are not intended for use in humans.

**Testing Performed by WiCell** 

recurring recurring and recurr						
Test Description	Test Provider	Test Method	Test Specification	Result		
Karyotype by G-banding	WiCell	SOP-CH-003	Expected karyotype	Pass		
	Result from report: This is an abnormal karyotype, with trisomy 13 as the only clonal					
			n all cells examined. The finding o			
	this culture is consistent with previous reports of inherent trisomy 13 in this cell line.					
Post-Thaw Viable Cell Recovery	WiCell	SOP-CH-305	≥ 15 Undifferentiated Colonies,	Pass		
			≤ 30% Differentiation			
Identity by STR	UW Molecular	PowerPlex 1.2	Consistent with known profile	Pass		
	Diagnostics Laboratory	System by				
		Promega				
Sterility - Direct transfer method	Apptec	30744	Negative	Pass		
Mycoplasma	Bionique	M250	No contamination detected	Pass		

Approval Date	Quality Assurance Approval		
27-August-2009	8/9/2017  X AMK  AMK  Qualify Assurance Signed by Klade, Anjelica		



## WiCell Cytogenetics Report: 001132-060109

NSCB 8909

**Report Date:** June 10, 2009

#### Case Details:

**Cell Line:** SA02-FTDL-1 (8909)

**Passage #:** 31

Date Completed: 6/9/2009 Cell Line Gender: female

Investigator: National Stem Cell Bank

**Specimen:** hESC on MEF feeder

**Date of Sample:** 6/1/2009


Test, Reason for: FTDL Release Testing

*Results:* 47,XX,+13

Completed by CLSp(CG), on 6/9/2009

Reviewed and interpreted by PhD, FACMG, on 6/9/2009

Interpretation: This is an abnormal karyotype, with trisomy 13 as the only clonal aberration detected. Trisomy 13 was found in all cells examined. The finding of trisomy 13 in this culture is consistent with previous reports of inherent trisomy 13 in this cell line.



**Cell:** S01-01

Slide: B

Slide Type: Karyotyping
Cell Results: 47,XX,+13

# of Cells Counted: 20

# of Cells Karyotyped: 4

# of Cells Analyzed: 8

**Band Level: 450-550** 

Results Transmitted by Fax / Email / Post Sent By:

QC Review By:

Date:\_\_\_\_\_Sent To:

Results Recorded:





University of Wisconsin Hospital and Clinics

Short Tandem Repeat Analysis\*

Sample Report: 8909-STR

UW HLA#: 61156

Sample Date: 06/18/09

Received Date: 06/18/09

Requestor: WiCell Research Institute

Test Date: 06/23/09

File Name: 090624

Report Date: 06/25/09

Amended Report: 07/24/09

Sample Name: (label on tube)

8909-STR

Description: DNA Extracted by WiCell

242.61 ug/mL; 260/280 = 1.87

Locus	Repeat #	STR Genotype		
D16S539	5, 8-15	12,14		
D7S820	6-14	10,12		
D13S317	7-15	9,11,14		
D5S818 7-15		12,12		
CSF1PO 6-15		11,12		
TPOX 6-13		8,9		
Amelogenin	NA	X,X		
TH01	5-11	9,9.3		
vWA	11, 13-21	14,16		

Comments: Based on the 8909-STR DNA submitted by WI Cell dated 06/18/09 and received on 06/18/09, this sample (UW HLA# 61156) matches the STR profile of the human stem cell line SA02 comprising 16 allelic polymorphisms across the 8 STR loci analyzed (Josephson, R. et al., BMC Biol. 2006 Aug 18;4:28). Consistent with published results on the human embryonic stem cell line SA02 (Josephson, R. et al., BMC Biol. 2006 Aug 18;4:28), the 7755-STR DNA sample displays the tri-allelic genotype (9,11,14) at the D13S317 loci with each allele having approximately equal amplification strengths. No STR polymorphisms other than those corresponding to the human SA02 stem cell line were detected and the concentration of DNA required to achieve an acceptable STR genotype (signal/ noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggest that the 8909-STR DNA sample submitted corresponds to the SA02 stem cell line and it does not appear to be contaminated with any other human stem cells or a significant amount of mouse feeder layer cells. Sensitivity limits for detection of STR polymorphisms unique to either this or other human stem cell lines is ~5%.

1-27-09

Manager Date

HLA/Molecular Diagnostics Laboratory

1

PhD, Director

Date

HLA/Molecular Diagnostics Laboratory

File: Final STR Report

<sup>\*</sup> Testing to assess engraftment following bone marrow transplantation was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only.

Test Facility: 1265 Kennestone Circle Marietta, GA 30066 This report is confidential. No part may be used for advertising or public announcement without written permission. Results apply only to the sample(s) tested.



Report Number 806290 Page 3 of 9

April 23, 2009

WiCell Research Institute

### STERILITY TEST REPORT

Sample Information:

hES Cells

2: SA02-FTDL-1, #2974

Date Received: Date in Test:

April 07, 2009 April 08, 2009 April 22, 2009

Date Completed:
Test Information:

Test Codes: 30744, 30744A

Immersion, USP / 21 CFR 610.12 Procedure #: BS210WCR.201

TEST PARAMETERS	PRODUCT			
Approximate Volume Tested	0.5 mL	0.5 mL		
Number Tested	2	2		
Type of Media	SCD	FTM		
Media Volume	400 mL	400 mL		
Incubation Period	14 Days	14 Days		
Incubation Temperature	20 °C to 25 °C	30 °C to 35 °C		
RESULTS	2 NEGATIVE	2 NEGATIVE		

Page 1 Signed		Page 1 Signed		
QA Reviewer	Date	Technical Reviewer	Date	



#### BIONIOUE TESTING LABORATORIES, INC.

APPENDIX IV

Page 1 of 2

Document#:

DCF3013D

Edition#: Effective Date: 10 07/15/2003

Title:

M-250 FINAL REPORT SHEET

#### M-250 FINAL REPORT

Direct Specimen Culture Procedure 3008, 3011, 3013

TO: Wicell OA

BTL SAMPLE ID#: 57734

P.Q.#:

DATE REC'D:

06/16/2009

TEST/CONTROL ARTICLE:

\$A02-FTDL-01-H #8909

LOT#: NA

DIRECT CULTURE SET-UP (DAY 0)	DATE: 06/17/2009
INDICATOR CELL LINE (VERO)	SEE DNA FLUOROCHROME RECORD SHEET
	DATE
THIOGLYCOLLATE BROTH	DAY 7 + 🕒 <u>06/24/2009</u>
	DAY 28 + 🗇 <u>07/15/2009</u>
BROTH-FORTIFIED COMMERCIAL	
0.5 ml SAMPLE	DAY 7 + $\bigcirc$ 06/24/2009
6.0 mL BROTH	DAY 28 + 🗇 <u>07/15/2009</u>
BROTH-MODIFIED HAYFLICK	
0.5 mL SAMPLE	DAY 7 + 🕒 <u>06/24/2009</u>
6.0 pl Broth	DAY 28 + 🖯 <u>07/15/2009</u>
BROTH-HEART INFUSION	
0.5 mL SAMPLE	DAY 7 + 😑 <u>06/24/2009</u>
6.0 ml BROTH	DAY 28 + 🕒 <u>07/15/2009</u>
(See Reverse)	

Document#:

DCF3013D

Edition#:

1.0

Effective Date:

07/15/2003

Title:

M-250 FINAL REPORT SHEET

SAMPLE ID#: 57734		AEROBIC	MICROAEROPHILIC	DATE
AGAR PLATES-FORTIFIED COMMERCIAL	DAY 7 DAY 14 DAY 21	+ + + +	+ 0 + 0 + 0	06/24/2009 07/01/2009 07/08/2009
AGAR PLATES-MODIFIED HAYFLICK	DAY 7 DAY 14 DAY 21	† † † † †	† (D) † (D)	06/24/2009 07/01/2009 07/08/2009
AGAR PLATES-HEART INFUSION	DAY 7 DAY 14 DAY 21	† 0 † 0 †	† <b>©</b> † © † ©	06/24/2009 07/01/2009 07/08/2009
BROTH SUBCULTURES (DAY 7)		DATE: <u>06/</u>	/24/2009	
AGAR PLATES-FORTIFIED COMMERCIAL	DAY 7 DAY 14 DAY 21	+ + ÷	+ + +	07/01/2009 07/08/2009 07/15/2009
AGAR PLATES-MODIFIED HAYFLICK	DAY 7 DAY 14 DAY 21	+ + + +	+ OO + OO	07/01/2009 07/08/2009 07/15/2009
AGAR PLATES-HEART INFUSION	DAY 7 DAY 14 DAY 21	+ + +	* © * ©	07/01/2009 07/08/2009 07/15/2009

RESULTS: No detectable mycoplasmal contamination

7.15.09

Date

Laboratory Director

Ph.D.

M-250 Procedural Summary: The objective of this test is to assortain whether or not detectable mycoplasmas are present in an in vitro call culture sampla, he it a primary culture, hybridoma, master seed stock or call line. This procedure combines an indirect DNA stoining approach to detect non-cultivable mycoplasmas with a direct culture methodology utilizing three different mycoplasmal media formulations. The indirect approach involves the importance of the sample into a mycoplasmal rate of the control indirect culture expect of the test utilizes three different mycoplasmal media including both breth and sgar formulations. The sample is inequalated into each of the 3 breth formulations and also onto duplicate plates (6.1 mL/plate) for each of the 3 agar formulations. Subculture from broth to from agar formulations and also onto duplicate plates (6.1 mL/plate) for each of the 3 microaccophillically in order to detect any colony forming units morphologically indicative of mycoplasmal contamination. Insurance of the final report with signature of the Laboratory Director signifies that the required controls were parformed concurrently with the test sampla(s) as detailed in the referenced SGFs and that all test conditions have been found to meet the required acceptance criteria for a valid tast, including the appropriate results for the positive and negative controls.



### BIONIOUE TESTING LABORATORIES. INC

APPENDIX I Document #: Edition #: Effective date: Citle:	DCF3008A 06 9/17/2003 DNA FLUOR	OCHROME A	SSAY RESU	ILTS	
		OCHROME AS res 3008, 30			
Sample ID # <u>57734</u>	<u>M-250</u>	Date Rec'd:	06/16/2009	P.O. # <b>RP2</b> 7	<u>752</u>
Indicator Cells Inoculated:	Date/Initials:	6/18/09	1 115.	· 	
Fixation:	Date/Initials:	6/22/09	_/_ KG	· .	
Staining:	Date/Initials:	6/22/09	/K6_	 	•
TEST/CONTROL ARTICLE:					
SA02-FTDL-01-H #89	09	. •			
LOT# <u>NA</u>					
<u>Wicell QA</u> WiCell Research Instit	tuto		• •	•	
505 S. Rosa Rd., Suite	<del></del>		Phone	608-441-8019	· · · · ·
Madison, WI 53719	L. M. Constitution of the		Fax #:	608-441-8028	
	•		,		
DNA FLUOROCHROME	ASSAY RESULT	S:			•
NEGATIVE:	A reaction wi	th staining li nal contamin	mited to the : ation.	nuclear region,	which indicates
POSITIVE:	A significant mycoplasmal			aining which str	rongly suggests
INCONCLUS	SIVE:				•
Management of the control of the con				ining consistent degeneration.	t with low - level
		er microbial	contaminant	or viral CPE. I	t with bacterial, Morphology not
COMMENTS:					
4					